Identification of an Antiretroviral Small Molecule That Appears To Be a Host Targeting Inhibitor of HIV 1 Assembly
The success of antiretroviral treatment for HIV 1 is at risk of being undermined by the growing problem of drug resistance. Thus, there is a need to identify antiretrovirals that act on viral life cycle stages not targeted by drugs in use, such as the events of HIV 1 Gag assembly. To address this gap, we developed a compound screen that recapitulates the intracellular events of HIV 1 assembly, including virus host interactions that promote assembly. This effort led to the identification of a new chemotype that inhibits HIV 1 replication at nanomolar concentrations, likely by acting on assembly. This compound colocalized with Gag and two host enzymes that facilitate capsid assembly. However, resistance selection did not result in compound specific mutations in gag, suggesting that the chemotype does not directly target Gag. We hypothesize that this chemotype represents a first in class inhibitor of virus production that acts by targeting a virus host complex important for HIV 1 Gag assembly. ABSTRACT Given the projected increase in multidrug resistant HIV 1, there is an urgent need for development of antiretrovirals that act on virus life cycle stages not targeted by drugs currently in use. Host targeting compounds are of particular interest because they can offer a high barrier to resistance. Here, we report identification of two related small molecules that inhibit HIV 1 late events, a part of the HIV 1 life cycle for which potent and specific inhibitors are lacking. This chemotype was discovered using cell free protein synthesis and assembly systems that recapitulate intracellular host catalyzed viral capsid assembly pathways. These compounds inhibit replication of HIV 1 in human T cell lines and peripheral blood mononuclear cells, and are effective against a primary isolate. They reduce virus production, likely by inhibiting a posttranslational step in HIV 1 Gag assembly. Notably, the compound colocalizes with HIV 1 Gag in situ; however, unexpectedly, selection experiments failed to identify compound specific resistance mutations in gag or pol, even though known resistance mutations developed upon parallel nelfinavir selection. Thus, we hypothesized that instead of binding to Gag directly, these compounds localize to assembly intermediates, the intracellular multiprotein complexes containing Gag and host factors that form during immature HIV 1 capsid assembly. Indeed, imaging of infected cells shows compound colocalized with two host enzymes found in assembly intermediates, ABCE1 and DDX6, but not two host proteins found in other complexes. While the exact target and mechanism of action of this chemotype remain to be determined, our findings suggest that these compounds represent first in class, host targeting inhibitors of intracellular events in HIV 1 assembly. IMPORTANCE The success of antiretroviral treatment for HIV 1 is at risk of being undermined by the growing problem of drug resistance. Thus, there is a need to identify antiretrovirals that act on viral life cycle stages not targeted by drugs in use, such as the events of HIV 1 Gag assembly. To address this gap, we developed a compound screen that recapitulates the intracellular events of HIV 1 assembly, including virus host interactions that promote assembly. This effort led to the identification of a new chemotype that inhibits HIV 1 replication at nanomolar concentrations, likely by acting on assembly. This compound colocalized with Gag and two host enzymes that facilitate capsid assembly. However, resistance selection did not result in compound specific mutations in gag, suggesting that the chemotype does not directly target Gag. We hypothesize that this chemotype represents a first in class inhibitor of virus production that acts by targeting a virus host complex important for HIV 1 Gag assembly.
Journal of Virology